AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$AARD

Aardvark Therapeutics, Inc.

Price · $AARDvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $AARD in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $AARD in the last 30 days.

Top stories · $AARDMore →
MAY 18·TipRanksHigh

FDA Clinical Hold, Competitive Pressure Drive Aardvark Therapeutics Downgrade as Price Target Slashed from $18 to $4

Bank of America Securities analyst Tazeen Ahmad downgraded Aardvark Therapeutics to a Sell rating and slashed its price target from $18 to $4. This downgrade is due to an FDA clinical hold on the company's lead program, ARD-101, following cardiac issues in trials. Increased regulatory hurdles and growing competition from other treatments for Prader-Willi syndrome also contributed to the revised outlook.

MAY 15·The Manila Times

Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold

Aardvark Therapeutics announced that the FDA has placed a full clinical hold on its investigational new drug application (IND) for ARD-101, impacting its Phase 3 HERO trial and open-label extension trial for Prader-Willi Syndrome. The company plans to unblind clinical data from both trials to inform the next steps for its ARD-101 program while engaging with the FDA to resolve the hold. Aardvark currently has $91.2 million in cash equivalents, which is expected to fund operations into mid-2027.

MAR 2·Investing.com

Morgan Stanley downgrades Aardvark Therapeutics stock rating on trial pause

Morgan Stanley downgraded Aardvark Therapeutics (NASDAQ:AARD) from Overweight to Equalweight and cut its price target to $7.00 from $29.00 following the company's voluntary pause of its Phase 3 HERO trial due to reversible cardiac observations in a healthy volunteer study. Despite other firms like B.Riley and Raymond James maintaining positive ratings, RBC Capital also downgraded the stock, reflecting increased uncertainty regarding the drug's path forward. The company, currently trading down 72% from its 52-week high, plans to meet with the FDA and provide an update in Q2 2026.

News on $AARD